Optimi Health exports psilocybin to United Kingdom
Analysis based on 25 articles · First reported Jun 02, 2026 · Last updated Jun 10, 2026
The successful export of psilocybin by Optimi Health to the United Kingdom for clinical trials is a positive development for the company, potentially increasing its market share in the regulated psychedelic medicine sector. This expansion into new international markets, following existing supply to Australia and Canada, could lead to increased revenue and investor confidence in Optimi Health. The broader pharmaceutical and biotechnology industries may see increased interest in psychedelic therapies as regulatory approvals and clinical trials progress.
Optimi Health, a pharmaceutical manufacturer of regulated psychedelic drug products, has completed its first export of naturally derived psilocybin to the United Kingdom. This shipment, consisting of psilocybin biomass and 5mg capsules, is intended to support a planned Phase 2 clinical trial in the United Kingdom for treatment-resistant depression. The product was manufactured at Optimi Health's GMP facility in British Columbia, Canada, and the export was authorized by Canada — Health Canada and the United Kingdom — Home Office. This marks an expansion of Optimi Health's international reach, as its psilocybin capsules are already prescribed to patients in Australia and accessible in Canada. The company also recently completed a GMP production run, with portions earmarked for clinical research in the United States and Europe.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard